AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03821779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social exposure in a virtual reality setting
Description: Subjects will give a 5 minutes oral presentation on the subject of their choice to a virtual reality panel composed of 5 examiners displaying no facial emotional reaction, after a 5 minutes period of silent waiting in front of the examiners. This waiting period is expected to elicit anticipation-type of social anxiety.
Study NCT03821779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG recording
Description: EEG will be recorded with a standard 16-electrodes cap. Recordings will start before the 5 minutes waiting period and continue throughout oral presentation and recovery. The recovery period will be used as a baseline control
Study NCT03821779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Psychometric evaluation
Description: Subjects will be evaluated prior to inclusion using the following assessment tools~* Anamnestic Association for Methodology and Documentation in Psychiatry (AMDP) questionnaire~* Mini International Neuropsychiatric Interview (MINI 6.0, for psychiatric diagnoses)~* Liebowitz Social Anxiety Scale (LSAS)~* Montgomery Asberg Depression Rating Scale (MADRS)~* Brief Anxiety Scale of Tyrer (BAS)~* State-Trait Anxiety Inventory (STAI A-B)~* Global Assessment of Functioning (GAF)
Study NCT01778010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine 50 mg
Description: Cocaine (50 mg/day)
Study NCT04178850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB242
Description: GB242: Dosing of 3 mg/kg, intravenous drip, to be completed over 120 minutes, dosing at weeks 0, 2, 6, 14 and 22, a total of 5 doses; MTX:Dosage and administration at enrollment are maintained (10\~15mg/week), oral administration, a total of 30 doses; Folic acid: 5-10mg/week, oral administration, a total of 30 doses
Study NCT04178850 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Infliximab: Dosing of 3 mg/kg, intravenous drip, to be completed over 120 minutes, dosing at weeks 0, 2, 6, 14 and 22, a total of 5 doses; MTX:Dosage and administration at enrollment are maintained (10\~15mg/week), oral administration, a total of 30 doses; Folic acid: 5-10mg/week, oral administration, a total of 30 doses
Study NCT02896010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sweetch App + DBWS
Description: Usual care for prediabetes management, Sweetch app, weight monitoring via digital body weight scale (DBWS).
Study NCT02896010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sweetch App Alone
Description: Usual care for prediabetes management, Sweetch app alone.
Study NCT02837991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-014
Study NCT04180280 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral self-regulation Phone counseling to improve HIV care
Description: Participants receive 5 sessions of behavioral counseling to improve HIV care. Counseling is delivered using phone calls by a trained adherence and care engagement counselor.
Study NCT04180280 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral self-regulation Office counseling to improve HIV care
Description: Participants receive 5 sessions of behavioral counseling to improve HIV care. Counseling is delivered in clinical care offices s by a trained adherence and care
Study NCT04564053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNA043
Description: Single intra-articular injection on Day 1
Study NCT04564053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single intra-articular injection on Day 1
Study NCT02845869 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Therapy
Description: The therapeutic light will be turned off but the system will produce similar noises and mild heat.
Study NCT04564053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intra-articular injection on Day 1
Study NCT03144453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Injectable Product
Description: Patients receive sugammadex at the end of the surgery
Study NCT03144453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine, Atropine
Description: Patients receive neostigmine+atropine at the end of the surgery
Study NCT02744794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal Cooling System
Description: Treatment with cryotherapy.
Study NCT04030845 — intervention group
Intervention type: PROCEDURE
Intervention: breast reconstruction
Description: The breast reconstruction mainly included autologous tissue flaps (latissimus dorsi myocutaneous flaps, pedicled tansverse rectus abdominis myocutaneous flaps, free transverse rectus abdominis musculocutaneous flaps, deep inferior epigastric artery perforator flaps, etc.), implant based breast reconstruction, autologous flaps combined with implant reconstruction, fat graft, etc.
Study NCT01101074 — intervention group
Intervention type: OTHER
Intervention: This is non-intervention observational study
Description: This is non-intervention observational study
Study NCT00837330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab 0.5 or 0.3 mg/0.05 cc
Description: ranibizumab 0.5 or 0.3 mg/0.05 cc administered intraocularly on a monthly basis for 3 months, followed by monthly examination with the option of further ranibizumab treatment or other therapies at the discretion of the treating physician
Study NCT02919293 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (adjuvant-free)
Description: 30μg /dose, Intramuscular
Study NCT02919293 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine(adjuvant)
Description: 0.5ml /dose, Intramuscular
Study NCT02456623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Home-based session targeting the parent
Study NCT03390491 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OnTrack>TheGame (OTG)
Description: OTG clients will be informed that the game can be played on a computer or a tablet and the time estimate for completing the game is approximately 5-8 hours. OnTrack>The Game offers players the opportunity to immerse in a fictional neighborhood that centers around four domains for supportive recovery as defined by SAMHSA: health, home, purpose and community. The player interacts with other game characters including new acquaintances, friends/peers, a family member, and a treatment team, allowing the player to practice social and communication skills, while fostering personal relationships and building a support network. Additionally, the game provides players with helpful resources including psychoeducation materials and videos of real people who have experienced a first episode of psychosis, sharing their stories of hope and recovery. As a whole, the game provides a safe environment to promote goal attainment and recovery.
Study NCT03390491 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Recovery Videos (RV)
Description: As described, RV clients will have access to a website that includes recovery videos and static psychoeducation materials. In this condition, mental health providers will also ask about possible reactions to viewing the recovery videos and information on the website.
Study NCT01113957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888
Description: Arm-A subjects will be given ABT-888 on Days 1 -7 every 28 days orally
Study NCT02456623 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Attention condition with newsletters and support phone calls
Study NCT00513344 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark Chocolate
Description: 1 portion
Study NCT01113957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated liposomal doxorubicin
Description: Arm B subjects randomized to pegylated liposomal doxorubicin on Day 1, every 28 days intravenously.
Study NCT01113957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Arm A subjects will be given temozolomide on days 1-5 every 28 days orally with ABT-888
Study NCT03432689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Single-pulse transcranial magnetic stimulation and theta-burst stimulation
Study NCT03432689 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Single-pulse transcranial magnetic stimulation and theta-burst stimulation
Study NCT03432689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycloserine
Description: Cycloserine 100mg
Study NCT04030845 — intervention group
Intervention type: PROCEDURE
Intervention: oncoplastic breast-conserving surgery
Description: The oncoplastic breast-conserving surgery were mainly those surgeries using volume displacement or volume replacement techniques.
Study NCT03432689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo capsule matched to cycloserine capsule
Study NCT03964129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Avance Nerve Graft with Autologous BMAC
Description: The Avance Nerve Graft will be inserted in the area of nerve injury. Between 40 to 60 ml of Bone Marrow Aspirate from the anterior or posterior iliac crest of the pelvis will be harvested. Using SmartPrep centrifuge and 60 ml BMAC kit, 7 to 10 ml of final BMAC will be obtained. Of the 7 to 10 ml of final BMAC that is yielded, half (3.5 to 5 ml) of the final concentrate, will be injected on top of the Avance Nerve Graft following coaptation. The second half (3.5 to 5 ml) of the final concentrate will be inserted into a sterile tube containing culture media and shipped overnight to Cleveland Clinic Lerner Research Institute for cell processing and colony assay to confirm that the BMAC indeed contains autologous bone marrow stem cells.
Study NCT01673945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-guided fine needle aspiration
Description: Each patient will undergo examination with the CLA-EUS or the FV-EUS, which will be selected based on the randomization process. FV-EUS will be performed using the newly available FV -EUS scope (TGF-Y0001-UC) that is compatible with last generation Aloka alpha 10. First, search of the presumed lesion will be performed and once visualize, its characteristics (size, echogenicity, margins, etc) will be recorded on data collection sheet. Fine needle aspiration will be performed under EUS guidance using a 19- ,22- or a 25-gauge fine needle or procore needles depending on endoscopist's preference
Study NCT01056484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Relapse Prevention for Alcohol Dependence
Description: All subjects receive outpatient standard of care (SOC) therapy for alcohol dependence. Experimental subjects also receive the Mindfulness Meditation Relapse Prevention ('meditation') intervention. The intervention is an extension of existing meditation-based therapies for stress, relapse prevention in addictive disorders, and depression. It has been patterned after Mindfulness Based Relapse Prevention and tailored to the specific needs of alcoholics. Its curriculum includes both meditation and traditional cognitive therapy relapse prevention components. The intervention consists of an 8-week, manualized meditation course (2 hours/week group sessions) guided by trained instructors. In addition, experimental subjects are asked to meditate at-home (30 min/day, 6 days/week) during the study.
Study NCT01056484 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wait-list control
Description: 'Standard of care' (SOC) outpatient therapy for alcohol dependence is provided to all subjects through their outpatient treatment centers and as recommended by their regular providers. Subjects in the control group receive SOC only. Subjects in the experimental arm will receive the study meditation intervention in addition to SOC.
Study NCT01626287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frozen perineal pad
Description: Frozen ice pads will be provided as per participants' request
Study NCT01626287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm water soaked Black Tea Bags
Description: warm water soaked black tea bags will be provided to participants' as per their request
Study NCT00875524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD dengue vaccine serotypes (1, 2, 3, 4).
Description: 0.5 mL, Subcutaneous
Study NCT00875524 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide
Description: Each at 0.5 mL, Subcutaneous, respectively
Study NCT01673945 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided fine needle aspiration
Description: Each patient will undergo examination with the CLA-EUS or the FV-EUS, which will be selected based on the randomization process. FV-EUS will be performed using the newly available FV -EUS scope (TGF-Y0001-UC) that is compatible with last generation Aloka alpha 10. First, search of the presumed lesion will be performed and once visualize, its characteristics (size, echogenicity, margins, etc) will be recorded on data collection sheet. Fine needle aspiration will be performed under EUS guidance using a 19- ,22- or a 25-gauge fine needle or procore needles depending on endoscopist's preference
Study NCT03512925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized debriefing session of coercive measures
Description: Debriefing session following the developed guidelines including setting and themes.
Study NCT00682461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Marketed nicotine replacement therapy formulation
Study NCT00682461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine prototype
Study NCT04116463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program (CDSMP)
Study NCT04116463 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial Self-Management Program (FSMP)
Study NCT02642653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovastatin
Description: Once per day dosing
Study NCT01006408 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low Level Laser
Description: Low Level Laser twice a week for 8 weeks
Study NCT01006408 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Placebo followed by Low Level Laser
Description: Placebo twice a week for 4 weeks then crossover to Low Level Laser twice a week for 4 weeks
Study NCT01879657 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATATE injection and PET scan
Description: 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image Neuroendocrine tumors by Positron Emission Tomography.
Study NCT02451475 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amitriptyline
Description: Amitriptyline 25 mg/day
Study NCT02451475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: Venlafaxine 75 mg/day
Study NCT02451475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Paroxetine 25 mg/day
Study NCT02677389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational material regarding physical activity and standardized emails with wellness tips and information on stress management
Study NCT02677389 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive educational material regarding physical activity and standardized emails with wellness tips and information on stress management
Study NCT02677389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive email and technical or how-to support from study coordinator
Study NCT02677389 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Device
Description: Wear a Fitbit web-integrated physical activity tracker
Study NCT02677389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02677389 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02677389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02677389 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03821779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale of anxiety
Description: Subjects will be asked to rate their anxiety levels~* immediately before (5 minutes of silent waiting),~* during~* and after the 5-minute oral presentation (recovery)
Study NCT04410536 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Symptomatic drugs
Description: indomethacin suppository 50-100 mg or an oral triptan, on maximum 3 days/10 days, only in case of very severe headache- and to use metoclopramide
Study NCT04410536 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bridge therapy
Description: prednisone 25 mg , 2 tablets after breakfast for 5 days, one tablet for 3 days, half tablet for 2 days ; bromazepam 1.5 mg, 1 tablet after breakfast, lunch and dinner for every day; pantoprazole 40 mg, 1 tablet after dinner every day
Study NCT04410536 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness program
Description: home based withdrawal program
Study NCT02642653 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once per day dosing
Study NCT03584893 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sampling for Cholestanol Analysis
Description: Cholestanol analysis will be performed to see the Rate of juvenile cataract patients whose cholestanol test result is above threshold (3.75 mg/mL) and suspected CTX cases
Study NCT00549419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
Description: The Control group will be assessed using the standard care of traditional vital signs
Study NCT00549419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goal-directed hemodynamic therapy
Description: Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
Study NCT00549419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
Study NCT00513344 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk Chocolate
Description: 1 portion
Study NCT00513344 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control (polyphenol-free) Chocolate
Description: one portion
Study NCT03671044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanosomal Docetaxel Lipid Suspension (75 mg/m2)
Description: Each vial containing lyophilized Docetaxel lipid powder, equivalent to 20 mg or 80 mg of anhydrous Docetaxel.
Study NCT03671044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanosomal Docetaxel Lipid Suspension (100 mg/m2)
Description: Each vial containing lyophilized Docetaxel lipid powder, equivalent to 20 mg or 80 mg of anhydrous Docetaxel.
Study NCT03671044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxotere® (100 mg/m2)
Description: Docetaxel Injection Concentrate; 20 mg/0.5 mL
Study NCT01548638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine ER
Description: The study will be performed using the 8mg and 16mg doses of galantamine hydrobromide-ER, which is currently marketed for the treatment of Alzheimer's disease. The dosing regimen, which follows FDA-approved guidelines, will be an initial 4 weeks of drug run-up at the lowest 8mg daily dose, followed by an additional one week of drug run-up at the higher dose of 16mg daily.~Participants will continue to take the 16mg daily during the 7-day quit week, for a total of 6 weeks of treatment with galantamine-ER.
Study NCT03030040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The self-help book: Williams, M. & Penman, D. (2011). Mindfulness: A practical guide to finding peace in a frantic world. London: Piatkus.
Description: Participants will be provided with a copy of the self-help book, and asked to read it and follow the activities outlined in it, over eight weeks. They will receive weekly standardized emails, to provide information about mindfulness and encouragement to engage with the self-help book.
Study NCT01814423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine-base 50 mg
Study NCT01814423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine-base 70 mg
Study NCT04653662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Earol
Description: Treated with Earol on both ears and subsequent removal after 6 days of application
Study NCT03015532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: HTX-011 (bupivacaine/meloxicam), via instillation
Study NCT03015532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Saline placebo via injection
Study NCT03015532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivicaine HCl
Description: Bupivacaine HCl without epinephrine